Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

About this update from Evolus, Inc. Common Stock

NEWPORT BEACH, Calif., May 11, 2026--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced "esteem"), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company’s entry into the international dermal filler market. The Estyme® collection includes four injectable HA gels that will cover a wide range of applications. The collection includes Estyme® Smooth and Estyme® Form, which are currently marketed in the United States under the brand Evolysse®, along with the debut of two products including Estyme® Lips and the flagship product in the line, Estyme® Sculpt, which is expecting U.S. FDA approval later this year. Developed for restoring mid-face volume, Estyme® Sculpt addresses one of the most in-demand treatment areas in aesthetics. Designed by Symatese, the innovative Cold-X® technology helps preserve the natural structure of the HA molecule, providing long-lasting, natural-looking results. The commercial launch follows the successful CE Mark certification under the European Medical Device Regulation (MDR), one of the most stringent regulatory frameworks globally, validating the safety, efficacy, and quality of the Estyme® collection. "With the commercial launch of Estyme®, we are entering a new phase of growth as a multi-product aesthetics company in Europe," said David Moatazedi, President and Chief Executive Officer of Evolus. "We are especially excited to introduce Estyme® Sculpt to practitioners, a product we believe has the potential to become a leader in mid-face volumizing treatments. By pairing this innovative technology with the commercial strength we’ve built with Nuceiva®, we are uniquely positioned among several companies with a neurotoxin and filler portfolio." Dr. Benji Dhillon, a prominent UK-based cosmetic surgeon and founder of the Define Clinic, commented, "The launch of Estyme® in Europe is an exciting advancement for practitioners. The Cold-X® technology is designed to preserve the integrity of the hyaluronic acid, which is important when aiming for refined, natural-looking outcomes. Having a versatile range of gels that can be used across different treatment areas gives practitioners greater ...

View stock analysis, news, and events for Evolus, Inc. Common Stock